Therapeutically blocking the IL-1RI or IL-1β has been utilized in 10 patients with Majeed syndrome and all have reported significant benefit with resolution of the inflammatory bone disease and normalization of inflammatory markers. Here, IL1B is linked to Majeed syndrome.